NASDAQ:BYSI - BeyondSpring Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$30.98 +3.81 (+14.02 %)
(As of 05/23/2018 08:00 AM ET)
Previous Close$27.17
Today's Range$27.00 - $30.98
52-Week Range$19.55 - $48.49
Volume23,800 shs
Average Volume16,802 shs
Market Capitalization$610.12 million
P/E RatioN/A
Dividend YieldN/A
Beta0.28

About BeyondSpring (NASDAQ:BYSI)

BeyondSpring logoBeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York.

Receive BYSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BYSI
CUSIPN/A
Phone646-528-4184

Debt

Debt-to-Equity RatioN/A
Current Ratio6.75
Quick Ratio6.75

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.23 per share
Price / Book25.19

Profitability

EPS (Most Recent Fiscal Year)($4.40)
Net Income$-91,760,000.00
Net MarginsN/A
Return on Equity-224.65%
Return on Assets-208.02%

Miscellaneous

Employees25
Outstanding Shares22,460,000

BeyondSpring (NASDAQ:BYSI) Frequently Asked Questions

What is BeyondSpring's stock symbol?

BeyondSpring trades on the NASDAQ under the ticker symbol "BYSI."

How were BeyondSpring's earnings last quarter?

BeyondSpring (NASDAQ:BYSI) issued its quarterly earnings data on Tuesday, April, 3rd. The company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.62) by $0.06. View BeyondSpring's Earnings History.

When is BeyondSpring's next earnings date?

BeyondSpring is scheduled to release their next quarterly earnings announcement on Monday, May, 28th 2018. View Earnings Estimates for BeyondSpring.

What price target have analysts set for BYSI?

4 equities research analysts have issued 12-month price targets for BeyondSpring's stock. Their predictions range from $50.00 to $60.00. On average, they expect BeyondSpring's stock price to reach $54.50 in the next twelve months. View Analyst Ratings for BeyondSpring.

What are Wall Street analysts saying about BeyondSpring stock?

Here are some recent quotes from research analysts about BeyondSpring stock:
  • 1. Maxim Group analysts commented, "BeyondSpring will be presenting P2 data (N=55) from study 105 comparing lead asset plinabulin to Neulasta on incidence of neutropenia. The data (detailed below) demonstrates that a single dose of Plinabulin protects against neutropenia at the same rate as Neulasta while producing lower rates of bone pain." (5/17/2018)
  • 2. According to Zacks Investment Research, "BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. " (4/5/2018)

Who are some of BeyondSpring's key competitors?

Who are BeyondSpring's key executives?

BeyondSpring's management team includes the folowing people:
  • Dr. Lan Huang, Co-Founder, Chairman & CEO (Age 47)
  • Mr. Edward Dongheng Liu, Chief Financial Officer
  • Ms. Amy Yang, Controller
  • Dr. Ramon W. Mohanlal M.D., Ph.D., MBA, Chief Medical Officer of BeyondSpring US (Age 60)
  • Dr. G. Kenneth Lloyd Ph.D., Chief Scientific Officer of BeyondSpring US (Age 74)

When did BeyondSpring IPO?

(BYSI) raised $4 million in an initial public offering on Thursday, March 9th 2017. The company issued 200,000 shares at $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) acted as the underwriter for the IPO.

Has BeyondSpring been receiving favorable news coverage?

Media headlines about BYSI stock have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. BeyondSpring earned a coverage optimism score of 0.09 on Accern's scale. They also gave media stories about the company an impact score of 47.80 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of BeyondSpring?

Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BeyondSpring's stock price today?

One share of BYSI stock can currently be purchased for approximately $30.98.

How big of a company is BeyondSpring?

BeyondSpring has a market capitalization of $610.12 million. The company earns $-91,760,000.00 in net income (profit) each year or ($4.40) on an earnings per share basis. BeyondSpring employs 25 workers across the globe.

How can I contact BeyondSpring?

BeyondSpring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 646-528-4184 or via email at [email protected]


MarketBeat Community Rating for BeyondSpring (BYSI)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  93 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  175
MarketBeat's community ratings are surveys of what our community members think about BeyondSpring and other stocks. Vote "Outperform" if you believe BYSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BYSI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BeyondSpring (NASDAQ:BYSI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for BeyondSpring in the last 12 months. Their average twelve-month price target is $54.50, suggesting that the stock has a possible upside of 75.92%. The high price target for BYSI is $60.00 and the low price target for BYSI is $50.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $54.50$54.50$54.50$54.00
Price Target Upside: 75.92% upside102.08% upside109.53% upside52.76% upside

BeyondSpring (NASDAQ:BYSI) Consensus Price Target History

Price Target History for BeyondSpring (NASDAQ:BYSI)

BeyondSpring (NASDAQ:BYSI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2018Maxim GroupReiterated RatingBuy$52.00MediumView Rating Details
4/3/2018HC WainwrightSet Price TargetBuy$60.00LowView Rating Details
12/5/2017Seaport Global SecuritiesInitiated CoverageBuy ➝ Buy$56.00MediumView Rating Details
7/14/2017Rodman & RenshawBoost Price TargetBuy ➝ Buy$43.00 ➝ $50.00MediumView Rating Details
(Data available from 5/23/2016 forward)

Earnings

BeyondSpring (NASDAQ:BYSI) Earnings History and Estimates Chart

Earnings by Quarter for BeyondSpring (NASDAQ:BYSI)

BeyondSpring (NASDAQ:BYSI) Earnings Estimates

2018 EPS Consensus Estimate: ($2.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.72)($0.72)($0.72)
Q2 20181($0.66)($0.66)($0.66)
Q3 20181($0.66)($0.66)($0.66)
Q4 20181($0.66)($0.66)($0.66)

BeyondSpring (NASDAQ BYSI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/28/2018        
4/3/2018Y 2017($0.62)($0.68)ViewListenView Earnings Details
11/9/2017Q3 2017($0.69)($0.68)ViewN/AView Earnings Details
8/21/2017Q2 2017($0.24)($0.39)ViewN/AView Earnings Details
5/22/2017Q1 2017($0.27)($2.66)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

BeyondSpring (NASDAQ:BYSI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

BeyondSpring (NASDAQ BYSI) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 1.29%
Insider Trading History for BeyondSpring (NASDAQ:BYSI)

BeyondSpring (NASDAQ BYSI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

BeyondSpring (NASDAQ BYSI) News Headlines

Source:
DateHeadline
BeyondSpring (BYSI) Receives Buy Rating from Maxim GroupBeyondSpring (BYSI) Receives Buy Rating from Maxim Group
www.americanbankingnews.com - May 17 at 2:51 PM
BeyondSpring to Present Positive Data From Prospective Phase 2 Trial Comparing Plinabulin to Neulasta for the Prevention of Chemotherapy-Induced Neutropenia at 2018 ASCO Annual MeetingBeyondSpring to Present Positive Data From Prospective Phase 2 Trial Comparing Plinabulin to Neulasta for the Prevention of Chemotherapy-Induced Neutropenia at 2018 ASCO Annual Meeting
finance.yahoo.com - May 17 at 10:44 AM
BeyondSpring Inc. (BYSI) Sees Hammer Chart Pattern: Time to Buy?BeyondSpring Inc. (BYSI) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - May 15 at 11:08 AM
 Brokerages Expect BeyondSpring (BYSI) Will Announce Earnings of -$0.73 Per Share Brokerages Expect BeyondSpring (BYSI) Will Announce Earnings of -$0.73 Per Share
www.americanbankingnews.com - May 13 at 1:22 AM
BeyondSpring (BYSI) Upgraded to Hold at ValuEngineBeyondSpring (BYSI) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - May 3 at 10:05 PM
BeyondSpring (BYSI) Receives Consensus Recommendation of "Buy" from BrokeragesBeyondSpring (BYSI) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 2 at 3:34 AM
 BeyondSpring (BYSI) Receives Average Rating of "Strong Buy" from Analysts BeyondSpring (BYSI) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - April 28 at 3:22 AM
BRIEF-BeyondSpring Says May Offer And Sell Up To 5 Mln Of Cos Ordinary Share From Time to TimeBRIEF-BeyondSpring Says May Offer And Sell Up To 5 Mln Of Co's Ordinary Share From Time to Time
www.reuters.com - April 26 at 10:09 AM
BeyondSpring to Present Neutropenia Clinical Trial Data on Lead Asset, Plinabulin, at 2018 ASCO Annual MeetingBeyondSpring to Present Neutropenia Clinical Trial Data on Lead Asset, Plinabulin, at 2018 ASCO Annual Meeting
finance.yahoo.com - April 26 at 10:09 AM
BeyondSpring CEO Reveals Novel Tumor TherapyBeyondSpring CEO Reveals Novel Tumor Therapy
finance.yahoo.com - April 25 at 3:49 PM
BeyondSpring (BYSI) Expected to Post Earnings of -$0.73 Per ShareBeyondSpring (BYSI) Expected to Post Earnings of -$0.73 Per Share
www.americanbankingnews.com - April 25 at 1:24 PM
BeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced NeutropeniaBeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced Neutropenia
finance.yahoo.com - April 17 at 10:47 AM
 BeyondSpring (BYSI) Receives Average Rating of "Strong Buy" from Brokerages BeyondSpring (BYSI) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - April 13 at 5:35 AM
Why BeyondSpring (BYSI) Could Be a Potential WinnerWhy BeyondSpring (BYSI) Could Be a Potential Winner
finance.yahoo.com - April 12 at 11:27 AM
BeyondSpring (BYSI) Now Covered by Maxim GroupBeyondSpring (BYSI) Now Covered by Maxim Group
www.americanbankingnews.com - April 9 at 11:32 PM
Q1 2018 Earnings Forecast for BeyondSpring Issued By Seaport Global Securities (BYSI)Q1 2018 Earnings Forecast for BeyondSpring Issued By Seaport Global Securities (BYSI)
www.americanbankingnews.com - April 9 at 1:34 AM
-$0.73 Earnings Per Share Expected for BeyondSpring (BYSI) This Quarter-$0.73 Earnings Per Share Expected for BeyondSpring (BYSI) This Quarter
www.americanbankingnews.com - April 8 at 3:10 PM
BeyondSpring (BYSI) Lifted to "Buy" at Zacks Investment ResearchBeyondSpring (BYSI) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 5 at 6:52 PM
BeyondSprings (BYSI) CEO Lan Huang on Q4 2017 Results - Earnings Call TranscriptBeyondSpring's (BYSI) CEO Lan Huang on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - April 5 at 8:54 AM
BeyondSpring Files Its 2017 Annual Report on Form 20-FBeyondSpring Files Its 2017 Annual Report on Form 20-F
finance.yahoo.com - April 4 at 5:11 PM
BeyondSpring (BYSI) Announces  Earnings ResultsBeyondSpring (BYSI) Announces Earnings Results
www.americanbankingnews.com - April 4 at 8:10 AM
BeyondSpring (BYSI) Given a $60.00 Price Target at HC WainwrightBeyondSpring (BYSI) Given a $60.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 3 at 1:20 PM
BeyondSpring (BYSI) Given Buy Rating at Maxim GroupBeyondSpring (BYSI) Given Buy Rating at Maxim Group
www.americanbankingnews.com - April 3 at 11:38 AM
BRIEF-Beyondspring Qtrly Loss Per Share $0.68BRIEF-Beyondspring Qtrly Loss Per Share $0.68
www.reuters.com - April 3 at 10:49 AM
BeyondSpring Provides Operational Update and Fourth-Quarter and Full-Year 2017 Financial ResultsBeyondSpring Provides Operational Update and Fourth-Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - April 3 at 10:49 AM
BeyondSpring (BYSI) Rating Increased to Hold at Zacks Investment ResearchBeyondSpring (BYSI) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 29 at 9:04 PM
BeyondSpring (BYSI) Scheduled to Post Quarterly Earnings on TuesdayBeyondSpring (BYSI) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - March 29 at 2:21 PM
Zacks: BeyondSpring (BYSI) Given Average Rating of "Strong Buy" by BrokeragesZacks: BeyondSpring (BYSI) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - March 29 at 10:07 AM
BeyondSpring appoints Edward Dongheng Liu as CFOBeyondSpring appoints Edward Dongheng Liu as CFO
seekingalpha.com - March 28 at 10:41 AM
BeyondSpring to Host Fourth-Quarter and Full-Year 2017 Financial Results Conference Call on April 3, 2018BeyondSpring to Host Fourth-Quarter and Full-Year 2017 Financial Results Conference Call on April 3, 2018
finance.yahoo.com - March 28 at 10:41 AM
BRIEF-Beyondspring Says, Co Appointed Edward Dongheng Liu As Its Chief Financial Officer, Effective ImmediatelyBRIEF-Beyondspring Says, Co Appointed Edward Dongheng Liu As Its Chief Financial Officer, Effective Immediately
www.reuters.com - March 27 at 10:53 AM
BeyondSpring Appoints Edward Dongheng Liu as Chief Financial OfficerBeyondSpring Appoints Edward Dongheng Liu as Chief Financial Officer
finance.yahoo.com - March 27 at 10:53 AM
Zacks: Brokerages Expect BeyondSpring (BYSI) to Announce -$0.76 EPSZacks: Brokerages Expect BeyondSpring (BYSI) to Announce -$0.76 EPS
www.americanbankingnews.com - March 22 at 3:23 PM
Maxim Group Reiterates $52.00 Price Target for BeyondSpring (BYSI)Maxim Group Reiterates $52.00 Price Target for BeyondSpring (BYSI)
www.americanbankingnews.com - March 19 at 1:54 PM
BeyondSpring (BYSI) PT Set at $60.00 by HC WainwrightBeyondSpring (BYSI) PT Set at $60.00 by HC Wainwright
www.americanbankingnews.com - March 19 at 1:18 PM
BeyondSpring Announces Initiation of Phase 3 Clinical Development for Plinabulin for Prevention of Chemotherapy-Induced NeutropeniaBeyondSpring Announces Initiation of Phase 3 Clinical Development for Plinabulin for Prevention of Chemotherapy-Induced Neutropenia
finance.yahoo.com - March 19 at 10:39 AM
BeyondSpring Chief Medical Officer Presents at Three Prominent Industry Conferences in March 2018BeyondSpring Chief Medical Officer Presents at Three Prominent Industry Conferences in March 2018
finance.yahoo.com - March 15 at 10:40 AM
Brokerages Expect Beyondspring Inc (BYSI) to Post ($0.76) Earnings Per ShareBrokerages Expect Beyondspring Inc (BYSI) to Post ($0.76) Earnings Per Share
www.americanbankingnews.com - March 14 at 3:10 AM
NewLink Genetics (NLNK) versus Beyondspring (BYSI) Head-To-Head AnalysisNewLink Genetics (NLNK) versus Beyondspring (BYSI) Head-To-Head Analysis
www.americanbankingnews.com - March 13 at 11:55 AM
Editas Medicine (EDIT) & Beyondspring (BYSI) Critical ContrastEditas Medicine (EDIT) & Beyondspring (BYSI) Critical Contrast
www.americanbankingnews.com - March 9 at 1:12 AM
Head-To-Head Analysis: Beyondspring (BYSI) & CytRx (CYTR)Head-To-Head Analysis: Beyondspring (BYSI) & CytRx (CYTR)
www.americanbankingnews.com - March 7 at 5:18 AM
Beyondspring Inc (BYSI) Expected to Post Earnings of -$0.76 Per ShareBeyondspring Inc (BYSI) Expected to Post Earnings of -$0.76 Per Share
www.americanbankingnews.com - March 5 at 11:46 AM
Beyondspring (BYSI) Given a $60.00 Price Target by HC Wainwright AnalystsBeyondspring (BYSI) Given a $60.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 1 at 10:24 PM
BRIEF-BeyondSpring Says Richard Brand Resigned As CFOBRIEF-BeyondSpring Says Richard Brand Resigned As CFO
www.reuters.com - February 23 at 10:32 AM
Analysts Expect Beyondspring Inc (BYSI) to Announce ($0.76) Earnings Per ShareAnalysts Expect Beyondspring Inc (BYSI) to Announce ($0.76) Earnings Per Share
www.americanbankingnews.com - February 12 at 5:28 AM
Beyondspring (BYSI) Stock Rating Reaffirmed by Maxim GroupBeyondspring (BYSI) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - February 7 at 8:36 AM
BeyondSpring to Present at Upcoming Investor ConferencesBeyondSpring to Present at Upcoming Investor Conferences
finance.yahoo.com - February 7 at 8:27 AM
BeyondSpring Summarizes Key Messages from KOL Call regarding Lead Asset Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced NeutropeniaBeyondSpring Summarizes Key Messages from KOL Call regarding Lead Asset Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia
finance.yahoo.com - February 5 at 5:05 PM
Zacks: Analysts Anticipate Beyondspring Inc (BYSI) Will Announce Earnings of -$0.76 Per ShareZacks: Analysts Anticipate Beyondspring Inc (BYSI) Will Announce Earnings of -$0.76 Per Share
www.americanbankingnews.com - January 30 at 7:10 PM
Zacks: Beyondspring Inc (BYSI) Given Average Rating of "Strong Buy" by BrokeragesZacks: Beyondspring Inc (BYSI) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 28 at 9:30 PM

SEC Filings

BeyondSpring (NASDAQ:BYSI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BeyondSpring (NASDAQ:BYSI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BeyondSpring (NASDAQ BYSI) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.